Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 6Carcinoma, Hepatocellular 2Uveal Melanoma 1Prostatic Neoplasms 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

Rituximab 45Cyclophosphamide 32fludarabine phosphate 28fludarabine 19ibrutinib 17Peripheral Blood Stem Cell Transplantation 17Lenalidomide 17venetoclax 13Mycophenolic Acid 10Cyclosporine 10acalabrutinib 9Whole-Body Irradiation 9Filgrastim 9obinutuzumab 7Bendamustine Hydrochloride 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Melphalan 6Prednisone 5Etoposide 5Busulfan 5zanubrutinib 4pirtobrutinib 4aldesleukin 4Vincristine 4Tacrolimus 4Indium 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × Thalidomide × Clear all
NCT00096018 2013-10-24

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Roswell Park Cancer Institute

Phase 1/2 Completed
43 enrolled 8 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡